Segment Information - Summary Of Disaggregated Research And Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue, Major Customer [Line Items]
Personnel related and stock-based compensation	$ 21,848	$ 20,072		$ 41,920	$ 33,015
Other research and development expenses	32,043	30,395		62,438	48,377
Research and Development Expense, Total	108,689	95,726	$ 74,226	204,415	145,112
Darovasertib
Revenue, Major Customer [Line Items]
External clinical development expenses	32,123	23,332		55,456	48,109
IDE397
Revenue, Major Customer [Line Items]
External clinical development expenses	2,893	3,515		6,407	7,531
IDE161
Revenue, Major Customer [Line Items]
External clinical development expenses	1,976	1,607		3,583	4,016
IDE849
Revenue, Major Customer [Line Items]
External clinical development expenses	7,397	4,765		12,162	685
IDE892
Revenue, Major Customer [Line Items]
External clinical development expenses	3,982	2,180		6,162	2,020
IDE034
Revenue, Major Customer [Line Items]
External clinical development expenses	3,205	6,808		10,013	106
IDE574
Revenue, Major Customer [Line Items]
External clinical development expenses	$ 3,222	$ 3,052		$ 6,274	$ 1,253